 DUBLIN, Ohio, June 03, 2020 GLOBE NEWSWIRE -- via NEWMEDIAWIRE -- Navidea Biopharmaceuticals, Inc. NYSE American: NAVB Navidea or the Company, a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that the results from the Companys first interim analysis of its ongoing NAV3-31 phase 2b clinical study will be presented as a poster at the European League Against Rheumatism EULAR Congress 2020. The aim of this interim analysis of the phase 2b study was to evaluate reproducibility and stability of imaging and to assess quantitative Tc99m tilmanocept uptake cut points that can reliably enable discrimination between joints of healthy people and RA patients. 